San Diego-based Traversa Therapeutics, a biopharmaceuticals firm developing RNA interference (RNAi) technology, said earlier this week that it has named Curt W. Bradshaw as Vice President of Research and Development. Bradshaw joins the firm from CovX, where he was Vice President of Chemistry. Bradshaw has also previously served at Ligand Pharmaceuticals and Abbott Laboratories.